Caplin Point Laboratories posts Q1 FY26 consolidated PAT at Rs. 152.80 Cr

Caplin Point Laboratories has reported total income of Rs. 533.36 crores during the period ended June 30, 2025

Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr

Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore

Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr

Cenexi reports an EBITDA breakeven for the quarter

JB Pharma Q1 FY26 PAT up at 14% to Rs. 202 Cr

Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr

India Formulation sales accounted for 34.2% of total consolidated sales for the quarter

Bliss GVS Pharma posts Q1 FY26 PAT higher at Rs. 43.03 Cr

Bliss GVS Pharma has reported total income of Rs. 242.92 crores during the period ended June 30, 2025

Ajanta Pharma reports Q1 FY26 consolidated PAT at Rs. 255.34 Cr

Ajanta Pharma has reported total income of Rs. 1,328.98 crores during the period ended June 30, 2025

Vijaya Diagnostic reports Q1 FY26 consolidated PAT at Rs. 38.33 Cr

The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal

Torrent Pharmaceuticals posts Q1 FY26 consolidated PAT higher at Rs. 548 Cr

Torrent Pharmaceuticals has reported total income of Rs. 3,141 crores during the period ended June 30, 2025

Piramal Pharma reports Q1 FY26 consolidated loss at Rs. 81.70 Cr

Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025